MSGID: 1:317/3 62720187   
   PID: hpt/lnx 1.9.0-cur 2019-01-08   
   TID: hpt/lnx 1.9.0-cur 2019-01-08   
    Combination of drugs for obesity and Typediabetes may be more   
   effective than a single therapy    
      
     Date:   
         May 3, 2022   
     Source:   
         University of Alberta   
     Summary:   
         Researchers have identified new drug combinations to treat   
         people with obesity and Type 2 diabetes. The goal is to develop   
         personalized prescriptions that are more effective than single   
         drugs and that can potentially replace more invasive treatments   
         such as bariatric surgery, especially for children.   
      
      
      
   FULL STORY   
   ==========================================================================   
   Canadian and German researchers are teaming up to identify new drug   
   combinations to treat people with obesity and Type 2 diabetes.   
      
      
   ==========================================================================   
   The goal is to develop personalized prescriptions that are more effective   
   than single drugs and that can potentially replace more invasive   
   treatments such as bariatric surgery, especially for children.   
      
   "As a pediatric endocrinologist, I can tell you we're seeing more and   
   more Type 2 diabetes in kids and adolescents, and it seems to be a   
   more aggressive form than adult onset diabetes, so we do need better   
   therapies to achieve even greater efficacy and degree of weight loss,"   
   said Andrea Haqq, a professor in the University of Alberta's Faculty of   
   Medicine & Dentistry.   
      
   The researchers recently published a paper that examines the potential of   
   several drugs that control incretins. These metabolic hormones stimulate   
   the body to produce insulin and use it effectively. They also suppress   
   appetite in order to control blood sugars and reduce weight.   
      
   The researchers conclude that combining the drugs has several advantages,   
   including higher effectiveness in at least some patients and fewer side-   
   effects.   
      
   Even a five per cent weight loss is considered clinically meaningful,   
   and patients in some of the combination drug trials are achieving 10 or   
   15 per cent, said Haqq, who is a member of the Alberta Diabetes Institute   
   and the Women and Children's Health Research Institute.   
      
   Haqq's laboratory is collaborating with that of Timo Mu"ller, director   
   of the Institute for Diabetes and Obesity at the Helmholtz Diabetes   
   Center and a researcher with the German Center for Diabetes Research in   
   Mu"nich, Germany.   
      
   As part of the collaboration with the Mu"ller team, first author Qiming   
   Tan, a PhD candidate in the U of A Faculty of Medicine & Dentistry,   
   will study for a term in Germany and a German student will join Haqq's   
   lab here.   
      
   Haqq and Tan recommend further research to identify why some individuals   
   respond differently to the drugs. Some racial and ethnic groups bear   
   a disproportionate burden of obesity and Type 2 diabetes, they said,   
   so more participants from these groups are needed in trials. Further   
   studies should also focus on how differences in biological sex affect   
   drug efficacy and safety.   
      
   In addition to drug combinations, the researchers are looking for non-   
   pharmacological solutions, such as how adding fibre to a person's diet   
   can slow weight gain and improve the effectiveness of existing diabetes   
   medications.   
      
      
   ==========================================================================   
   Story Source: Materials provided by University_of_Alberta. Original   
   written by Gillian Rutherford. Note: Content may be edited for style   
   and length.   
      
      
   ==========================================================================   
   Journal Reference:   
      1. Qiming Tan, Seun E. Akindehin, Camila E. Orsso, Richelle C. Waldner,   
         Richard D. DiMarchi, Timo D. Mu"ller, Andrea M. Haqq. Recent   
         Advances in Incretin-Based Pharmacotherapies for the Treatment of   
         Obesity and Diabetes. Frontiers in Endocrinology, 2022; 13 DOI:   
         10.3389/ fendo.2022.838410   
   ==========================================================================   
      
   Link to news story:   
   https://www.sciencedaily.com/releases/2022/05/220503141311.htm   
      
   --- up 9 weeks, 1 day, 10 hours, 50 minutes   
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)   
   SEEN-BY: 15/0 106/201 114/705 123/120 129/330 331 153/7715 218/700   
   SEEN-BY: 229/110 111 317 400 426 428 470 664 700 292/854 298/25 305/3   
   SEEN-BY: 317/3 320/219 396/45   
   PATH: 317/3 229/426